India, Aug. 15 -- Shares of Precigen Inc. (PGEN) are up over 50% at $2.77 in premarket hours, on news of the company securing FDA approval for its drug, Papzimeos, for the treatment of adults with recurrent respiratory papillomatosis.
Recurrent Respiratory Papillomatosis (RRP) is a rare, non-cancerous viral tumor in the airways caused by the human papillomavirus (HPV) that can potentially be life-threatening. It is estimated that approximately 27,000 adult patients in the US and more than 125,000 patients outside of the US are affected by RRP.
There is no known cure for RRP, and the typical treatment involves frequent surgeries, which do not target the root cause of the disease and often lead to considerable complications. PAPZIMEOS becom...